drugset / Trial / NCT05344664
Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma
NaSingle-groupSingle-blindTreatment
Summary
This is a single-center, single-arm, open-label Phase I study to evaluate the safety and efficacy of GPC3-CAR-T cell immunotherapy in the treatment of hepatocellular carcinoma.
Timeline
- Start
- 2022-04-14
- Primary completion
- 2024-10-14
- Completion
- 2025-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GPC3-CAR-T | Cell therapy | 3e+06 cells/kg | — |
| Subject | GPC3-CAR-T | Cell therapy | 1e+08 cells/kg | — |
Indications
No indication recorded.